Figure 2
Figure 2. Allogeneic tumor-specific lymphocytes can mediate tumor regression after intensive lymphodepleting preparatory regimen. C57BL/6 mice bearing B16 tumors were left untreated (A) or irradiated with 9 Gy TBI (B). Mice were left untreated as a control (NT) or injected on day 0 with vaccinia virus encoding hgp100 and exogenous IL-2 (VI) or injected with 106 or 107 (as indicated) allogeneic pmel-1b/d cells, vaccine, and IL-2 (PVI). *P < .001. **P < .05. All groups received syngeneic BMT with 106 unsorted bone marrow cells the day after the transfer of the effector cells (day 1). Results of tumor area are the mean of measurements of at least 5 mice per group (± SEM). Data are representative of 4 independent experiments.

Allogeneic tumor-specific lymphocytes can mediate tumor regression after intensive lymphodepleting preparatory regimen. C57BL/6 mice bearing B16 tumors were left untreated (A) or irradiated with 9 Gy TBI (B). Mice were left untreated as a control (NT) or injected on day 0 with vaccinia virus encoding hgp100 and exogenous IL-2 (VI) or injected with 106 or 107 (as indicated) allogeneic pmel-1b/d cells, vaccine, and IL-2 (PVI). *P < .001. **P < .05. All groups received syngeneic BMT with 106 unsorted bone marrow cells the day after the transfer of the effector cells (day 1). Results of tumor area are the mean of measurements of at least 5 mice per group (± SEM). Data are representative of 4 independent experiments.

Close Modal

or Create an Account

Close Modal
Close Modal